Study of the BDNF-Val66Met Polymorphism in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal

Study of the BDNF- Val66Met Polymorphism in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02146963

Enrollment

180

Registered

2014-05-26

Start date

2014-05-31

Completion date

2016-04-30

Last updated

2017-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Dependence

Brief summary

This study is complementary to the main study Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months After Alcohol Withdrawal NCT01491347. The purpose of this study is to evaluate the Bdnf gene - Val66Met polymorphism in subjects with alcohol dependence according to their alcohol consumption status 6 months after withdrawal (relapse or abstinence), in relation to the presence of psychiatric co-morbidities.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* participation to the study BDNF serum levels evolution during 6 months after alcohol withdrawal (main study) * criteria from the main study

Exclusion criteria

* criteria from the main study * released or out from the main study before the follow-up at 4 months after withdrawal

Design outcomes

Primary

Measure	Time frame
Frequency of the Bdnf gene Val/Val, Val/Met and Met/Met phenotypes as a function of relapse	at the time of inclusion

Secondary

Measure	Time frame
serum BDNF levels variations between inclusion and 6 months later (or 4 months if the participants does not come for the 4 months-follow-up).	6 months after alcohol withdrawal
existence of a psychiatric co-morbidity at the inclusion (major depression, schizophrenia, anxiety disorder)	at the time of inclusion
presence of a psychiatric co-morbidity at 6 months after withdrawal (major depression, schizophrenia, anxiety disorder)	6 month after alcohol withdrawal

Countries

France

Outcome results